ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Birmingham, AL, USA:

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...

Active, not recruiting
Leukemia
Drug: Dasatinib

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Birmingham, Alabama, United States and 173 other locations

single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).The dose escalation (Part A) of the study will explor...

Enrolling
Leukemia, Myeloid
Drug: CC-96191

Phase 1

Celgene
Celgene

Birmingham, Alabama, United States and 13 other locations

in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...

Enrolling
Leukemia, Myeloid, Acute
Chronic Myelomonocytic Leukemia
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

Phase 1, Phase 2

Aptose Biosciences

Birmingham, Alabama, United States and 33 other locations

GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...

Enrolling
Leukemia
Drug: GDX012
Drug: Chemotherapy Agents

Phase 1, Phase 2

Takeda
Takeda

Birmingham, Alabama, United States and 13 other locations

chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...

Active, not recruiting
Leukemia
Drug: Methotrexate
Drug: Thioguanine

Phase 2

Incyte
Incyte

Birmingham, Alabama, United States and 110 other locations

phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia...

Enrolling
Chronic Lymphocytic Leukemia
Drug: Loncastuximab Tesirine and Acalabrutinib

Phase 1

Mayur Narkhede

Birmingham, Alabama, United States

with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)
Drug: gilteritinib

Phase 3

Astellas
Astellas

Birmingham, Alabama, United States and 125 other locations

safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia...

Enrolling
LGLL - Large Granular Lymphocytic Leukemia
Aggressive NK Cell Leukemia
Drug: DR-01

Phase 1, Phase 2

Dren Bio

Birmingham, Alabama, United States and 33 other locations

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia...

Enrolling
Chronic Myeloid Leukemia
Drug: KRT-232
Drug: Dasatinib

Phase 1, Phase 2

Kartos Therapeutics
Kartos Therapeutics

Birmingham, Alabama, United States and 25 other locations

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (...

Enrolling
Leukemia, Myeloid, Acute
Drug: Bleximenib
Drug: Daunorubicin or Idarubicin

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Birmingham, Alabama, United States and 30 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems